A Phase 2, Multicenter, Open-label Study to Assess Safety and Preliminary Activity of Eribulin Mesylate in Pediatric Subjects With Relapsed/Refractory Rhabdomyosarcoma (RMS), Non-rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS) and Ewing Sarcoma (EWS)
Phase of Trial: Phase II
Latest Information Update: 20 Mar 2018
At a glance
- Drugs Eribulin (Primary)
- Indications Ewing's sarcoma; Rhabdomyosarcoma; Soft tissue sarcoma
- Focus Therapeutic Use
- Sponsors Eisai Inc
- 14 Mar 2018 Planned End Date changed from 30 Jun 2020 to 1 Jan 2021.
- 14 Mar 2018 Planned primary completion date changed from 30 Jun 2020 to 1 Jun 2020.
- 28 Feb 2018 New trial record